The current financial score of Evogene Ltd is 5.89. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 347.00K, representing a year-over-year decrease of 55.68%, while its net profit experienced a year-over-year decrease of 60.39%.
The current valuation score of Evogene Ltd is 9.41. Its current P/E ratio is -0.45, which is -94.14% below the recent high of -0.03 and -1780.38% above the recent low of -8.38.
The current earnings forecast score of Evogene Ltd is 8.00. The average price target is 2.15, with a high of 2.15 and a low of 2.15.
The current price momentum score of Evogene Ltd is 4.93. Currently, the stock price is trading between the resistance level at 0.61 and the support level at 0.40, making it suitable for range-bound swing trading.
The current institutional shareholding score of Evogene Ltd is 3.00. The latest institutional shareholding proportion is 2.31%, representing a quarter-over-quarter decrease of 76.01%.
The current risk assessment score of Evogene Ltd is 2.13. The company's beta value is 1.36. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.